PR93934

MONT-SAINT-GUIBERT, Belgium, Jan. 6, 2022 /PRNewswire=KYODO JBN/ --

Cognivia today announced a new name for the company formerly known as

Tools4Patient, which provides clinical trials solutions based on AI / ML that

account for individual patient personality traits, beliefs and perceptions. The

transition to Cognivia (

https://c212.net/c/link/?t=0&l=en&o=3403305-1&h=2344867879&u=https%3A%2F%2Fcognivia.com%2F&a=Cognivia

) more closely reflects the company's mission to "quantify the power of the

mind" and integrate this information into data analyses to optimize and

accelerate drug development.

Logo - https://mma.prnewswire.com/media/1719717/cognivia__Logo.jpg  

This name change expresses the evolution of the company since it was founded

eight years ago. As part of this maturation, Cognivia has built the evidence

basis for its technologies through multiple clinical trials and has become a

trusted partner of top pharma companies, biotechs and CROs. Cognivia's

solutions are focused in areas that have posed significant challenges to drug

development, including the placebo response and medication adherence in

clinical trials.

Cognivia also announces changes to its Board of Directors. Christian Jourquin,

a longtime senior leader at Solvay and past board member of ING Bank, becomes a

member of the Board. Graham Bunn, Ph.D., joins the team as Strategic Advisor to

the Board. Dr. Bunn has held several leadership roles in CROs and clinical

technology companies, including Vice President at Parexel International, Vice

President at Medidata, and Global Vice President at Quintiles, now IQVIA.

"While our name is changing and our team is expanding, we remain committed to

our core vision of delivering medicines to patients, while delivering value to

all stakeholders in the drug development process – from investors to

pharmaceutical companies to payers," says Dominique Demolle, CEO, Cognivia. "In

fact, Cognivia is doing what no one else is doing – developing a quantitative

understanding of patients as people and integrating these insights into

analysis of clinical trial data. For example,  Placebell(C)(TM) (

https://c212.net/c/link/?t=0&l=en&o=3403305-1&h=468446003&u=https%3A%2F%2Fcognivia.com%2F&a=Placebell%C2%A9%E2%84%A2

) uses predictive algorithms to mitigate the negative impact of the placebo

response and increase the study power of clinical trials, resulting in

increased success rates and decreased clinical trial timelines and cost."

About Cognivia

Cognivia (formerly Tools4Patient) began operation in 2014 after former

colleagues of a big pharma company set out to tackle some of the most

challenging issues that prevent drugs from reaching the marketplace. With the

support of key opinion leaders of various disciplines, including renowned

researchers at University of Sydney, Toulouse, INSERM and University of Liège,

the company today offers a comprehensive set of solutions that tackle the

overall clinical research value chain, from recruitment to data interpretation.

Cognivia aims to accelerate patient access to new therapies to improve

patients' lives by developing and commercializing methods and data analysis

solutions focused on the unique patient characteristics that influence their

response to treatment. The company's first technology is Placebell(C)(TM),

which characterizes the placebo response of patients. Cognivia is financed by

private investors and funds, including Sambrinvest and Innovation Fund. Learn

more at https://cognivia.com/.

Contact: Gwen Shields, gwen@altitudemarketing.com

SOURCE  Cognivia